Patents Assigned to KanonCure, Inc.
  • Patent number: 11866483
    Abstract: [Problem] To provide a composition and a cell sheet which are highly effective for inhibiting fibrosis, or cells having fibrosis-inhibiting activity, which are useful in regenerative medicine. [Solution] A medium containing IC-2 or a related compound is inoculated with mesenchymal stem cells or bone marrow mononuclear cells, and the cells are cultured for a prescribed period of time while the IC-2 or related compound is maintained at a constant concentration, thereby allowing a composition and a cell sheet which are highly effective for inhibiting fibrosis, or cultured cells having fibrosis-inhibiting activity, to be obtained.
    Type: Grant
    Filed: May 30, 2019
    Date of Patent: January 9, 2024
    Assignees: KanonCure, Inc., National University Corporation Tottori University
    Inventors: Yohei Kono, Noriko Itaba, Goshi Shiota
  • Patent number: 11213527
    Abstract: A novel therapeutic drug for malignant tumors, cancer stem cells, or fibrosis is obtained. A therapeutic drug for malignant tumors or cancer stem cells is used that includes at least one compound selected from the group consisting of compounds represented by formulas (1), (2), and (5), a salt thereof, or a solvate thereof. Alternatively, a therapeutic drug for fibrosis can be used that includes at least one compound selected from the group consisting of compounds represented by formulas (1), (2), and (5), a salt thereof, or a solvate thereof.
    Type: Grant
    Filed: March 25, 2015
    Date of Patent: January 4, 2022
    Assignees: National University Corporation Tottori University, KanonCure, Inc.
    Inventors: Goshi Shiota, Noriko Itaba, Keita Kanki, Kenzo Seto, Hiroki Shimizu, Yohei Kouno, Shinya Kunita, Zyunya Adumi, Tomohiko Sakabe, Kenichiro Abe, Minoru Morimoto, Hiroyuki Oka
  • Patent number: 10597398
    Abstract: To obtain a novel therapeutic drug for a malignant tumor or fibrosis. Used is a compound represented by formula (1), a salt thereof, or a solvate thereof. Also used is a therapeutic drug for a malignant tumor or a therapeutic drug for fibrosis, comprising a compound represented by formula (1), a salt thereof, or a solvate thereof.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: March 24, 2020
    Assignees: National University Corporation Tottori University, KanonCure, Inc.
    Inventors: Goshi Shiota, Noriko Itaba, Minoru Morimoto, Hiroyuki Oka, Kenichiro Abe, Hiroki Shimizu, Yohei Kouno, Satoshi Yokogi